The Ministry of Health reported that, after three years, the Argentina produced the vaccine against Hemorrhagic Fiber (FHA). The first batch consists of 7771 vials, that is, 77,710 doses, and has already been approved by the ANMAT. This serious viral disease is transmitted by a wild rodent and mainly affects the provinces of Buenos Aires, Santa Fe, Córdoba and La Pampa.
“We did what should never have stopped doing, production of an orphan vaccine should never have been stopped, a vaccine that responds to an Argentine disease with the journey that I have seen since I was in the vaccine program, ”said the Minister of Health, Carla Vizzotti, during a meeting with authorities from the National Institute of Human Viral Diseases ( INEVH).
In this sense, Pascual Fidelio, director of the National Administration of Laboratories and Institutes of Health (ANLIS) “Dr. Carlos Malbrán ”, stated:“ After a lot of work and an enormous effort by the workers of the Maiztegui institute, the vaccine is produced again. It was essential not to discontinue production and the support of the national government and the investment destined to carry out the remodeling of the production plant made it possible ”.
What is Argentine Hemorrhagic Fever (FHA)
This pathology is a severe viral illness, which I could reach up to a 30% fatalityThe only treatment that managed to cause a drop in mortality from 30 to 1% is convalescent plasma, although the number of donors decreased over the years.
The FHA is transmitted by a wild rodent, for which it is considered as a non-eradicable zoonotic disease, being that the areas with the greatest presence of this animal are in the provinces of Buenos Aires, Santa Fe, Córdoba and La Pampa. For this reason, the specialists warned that the most effective form of prevention is the Argentine Hemorrhagic Fever vaccine produced by the INEVH. Which it was only produced in Argentina.
“The synergy that was generated between each of the actors, the public production, the ANLIS Malbrán institute, the support and trust generated by the support of the ANMAT, and the support of the Ministry of Health so that today, after years of divestment, we can once again have the vaccine ready to distribute and to continue responding to the control of hemorrhagic fever in Argentina, ”said Vizzotti.
While the director of INEVH, María de los Ángeles Conti, added that “the institute returns to give answers to public health with an orphan vaccine, for a disease that claimed so many lives, as the only place of world production present in our calendar of vaccination”; for which A plan to reactivate the production plant was promoted, with an estimated investment of 47,575,000 pesos in equipment and services to remodel the facilities.